BPC-157 is one of the most-searched research peptides, and the questions that matter before ordering are the same as for any compound: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary of those points. It is not a guide to any use, not a claim that BPC-157 is an authorized drug or suitable for human use, and not legal or medical advice.

Identity starts with the named compound

BPC-157 — also written Body Protection Compound 157 — is a synthetic pentadecapeptide: a fifteen-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), described in the literature as derived from a protein found in human gastric juice, with the molecular formula C62H98N16O22. A procurement record should begin with the compound name, those identifiers, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document. Those fields establish identity for reconciliation; they do not verify biological activity or authorize a route of use.

Research status

BPC-157 has been studied primarily in laboratory animals, and human data is limited. The existence of preclinical research on a named compound documents scientific investigation; it does not establish that a third-party research material is an authorized drug product, equivalent to any study material, or suitable for human use. This article makes no claim about effects and is not a summary of research outcomes.

Canadian and anti-doping regulatory context

Health Canada’s April 2026 public advisory on unauthorized injectable peptides names BPC-157 among the products it identifies, and states that unauthorized drug products are illegal in Canada and have not been assessed for safety, efficacy, and quality by Health Canada. BPC-157 is not approved by any drug regulatory agency for human use. Separately, it has been prohibited by the World Anti-Doping Agency since 2022 under the S0 (non-approved substances) category, which is relevant to any research setting connected to sport.

The advisory is also explicit that a “research use only” label “does not make these products legal or exempt from regulatory requirements.” Vitatide’s research-use wording should be read the same way — a use boundary, not a claim of regulatory authorization — and determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.

Read the Health Canada public advisory

What a CoA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. For BPC-157 as for any compound, the checks are the same:

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.